Neuroscience

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

Treg cells
#Dementia #Neuroscience #Tregs

Study supports Treg enhancement as dementia treatment

A research study led by Dr Alireza Faridar and Dr Stanley Appel at the Houston Methodist Neurological Institute has demonstrated the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD).  Dr Fred Grossman, Chief Medical Officer at sponsors Coya,… Read More

#Editor's Choice #News

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

DDW Highlights: 17 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More

#Podcasts

Professor Stephen Wallace harvesting engineered bacteria for analysis.
#Bacteria #Neuroscience #Parkinson's #University of Edinburgh

Edinburgh team makes Parkinson’s drugs from plastic bottles

A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.  The approach harnesses bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.  It is the first time a natural, biological… Read More

#News #Trending News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

This week in Drug Discovery (9 – 13 March) 

News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW.  This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment.  The top stories: … Read More

#News

Neurons with Lewy bodies
#Alzheimer's #Mayo Clinic #Neuroscience #Women's health

Parkinson’s protein linked to faster Alzheimer’s progression in women

Alzheimer’s-related brain changes progressed up to 20 times faster in women who also had abnormal levels of a Parkinson’s-related protein, according to a Mayo Clinic study.  The findings suggest that when alpha-synuclein — a protein linked to Parkinson’s disease — accumulates alongside Alzheimer’s pathology, it may drive… Read More

#Editor's Choice #News

Microglia in the brain
#Alzheimer's #Dementia #Neuroscience #Texas A&M University Health Science Center

Could extracellular vesicle therapy prevent dementia?

A new research project will test whether extracellular vesicle (EV) therapy can prevent—or even reverse—inflammation in the brain linked to dementia.  Texas A&M Health and the Division of Research created the Dementia & Alzheimer’s Research Initiative (DARI) to prevent, more quickly detect and more effectively treat dementia. … Read More

#Editor's Choice #News

Neuron
#Funding #Lario Therapeutics #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

$2.4m funds neuronal calcium channel platform for Parkinson’s

Lario Therapeutics has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform.  With the proceeds of these awards, Lario is expanding its… Read More

#Business & Investment #News

Neuronal inclusions in Huntington’s disease
#Genetic diseases #Harness Therapeutics #Huntington's disease #Neuroscience

Harness Therapeutics nominates drug candidate for Huntington’s

Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD).  The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation.  Despite significant advances in understanding HD disease biology, there are currently… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Neuroscience #Phase I trial #Therapeutic Antibodies #VectorY Therapeutics

Vectorised antibody takes ‘innovative approach’ to ALS treatment

VectorY Therapeutics has announced that the first participant has been dosed in its Phase I/II PIONEER-ALS clinical trial of VTx-002 in people with amyotrophic lateral sclerosis (ALS).  VTx-002 is a first-in-class vectorised antibody designed to holistically target TDP-43 pathology in ALS recently granted FDA Fast… Read More

#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma… Read More

#Exclusive Content

Antibodies
#Alzheimer's #Neuroscience #Novartis #SciNeuro Pharmaceuticals #Therapeutic Antibodies

Novartis and SciNeuro collaborate on antibodies for Alzheimer’s

Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease.    The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More

#Business & Investment #News

Neurons
#Amyotrophic lateral sclerosis (ALS) #MND #Neuroscience #NRG Therapeutics #Phase I trial

Disease-modifying treatment for ALS enters Phase I

The first participants have been dosed in the first-in-human Phase I clinical trial of NRG Therapeutics’ lead candidate NRG5051, which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.   NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial… Read More

#News #Trending News

#Antidepressants #Depression #Drug targets #Korea University #Major depressive disorder #Neuroscience

New evidence revives abandoned depression drug target

New research has revealed that structurally novel neurokinin-1 receptor (NK1R) inhibitors reduce depressive-like behaviour and brain inflammation in mice.  For decades, scientists have investigated the NK1R as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs… Read More

#Editor's Choice #Editor's Pick #News